Hikma Pharmaceuticals Picks ViiV Healthcare's Rebecca Hall as CFO
By Michael Hennessey
Hikma Pharmaceuticals named ViiV Healthcare's Rebecca Hall as chief financial officer after a leadership reshuffle.
The London-listed pharmaceutical company on Thursday said Hall would join in the first quarter of 2027.
Hall is senior vice president and CFO at ViiV Healthcare, the HIV pharmaceutical company that is majority owned by GSK in a joint venture with Japan's Shionogi.
In February, Khalid Nabilsi stepped down as CFO of Hikma to become deputy chief executive officer in North America and Europe. This was part of a wider leadership reshuffle after Hikma reappointed Said Darwazah as chief executive in December 2025.
Areb Kurdi will continue as acting CFO until Hall joins, Hikma confirmed. Previous CFO Nabilsi will step down from the board at the end of 2026, but will continue to serve on the executive committee in his role as deputy CEO.
Write to Michael Hennessey at michael.hennessey@wsj.com
(END) Dow Jones Newswires
September 24, 2026 02:56 ET (06:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States